What's Going On With Takeda Stock On Friday?

Core Insights - Takeda Pharmaceutical Co Ltd's stock experienced volatility, dropping to $14.53 before recovering to approximately $15.47 [1] - The FDA approved Ionis Pharmaceuticals' Dawnzera for preventing hereditary angioedema attacks in patients aged 12 and older [1] Company Developments - Takeda has its own hereditary angioedema prevention drug, Takhzyro, which was approved by the FDA in 2018 and received expanded pediatric use approval in 2023 [2] - Takhzyro demonstrated an average of 87% reduction in attacks compared to placebo over 6.5 months in a study involving adult and adolescent patients [3] Market Context - Dawnzera will be available in the U.S. with a list price of $57,462 per dose, and is projected to achieve peak annual sales of $509 million by 2032 [4] - Takhzyro sales increased by 3.7% to 55.1 billion yen in Q2 2025 [4]